This article was originally published in The Gray Sheet
Executive SummaryReceives $2 mil. from the second closing of "an $11.9 mil. mezzanine financing"; the lead investor was Trinity Ventures Limited. The firm received $9.9 mil. from the first closing on Nov. 5, 1992 ("The Gray Sheet" Nov. 23, p. 18). The privately held, Miami, Florida-based company is conducting clinical trials for a line of small- and medium-diameter vascular grafts manufactured from spun polycarbonate urethane fibers. The company expects to begin commercial sales of the grafts in the Benelux countries and in France in April.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.